PROFESSIONAL EXPERIENCE

MDS Pharma Services (MDS PS), Bothell, WA                                                                                  1990 - 2005

(formerly Panlabs, Inc.)

Senior Director, Strategic Alliances                                                                                                  2004 - 2005

Senior Director of Pharmacology                                                                                                      2000 - 2004

Director of Pharmacology, Pharmacology Product Team Leader                                                      1995 - 2000

Principal Scientist, Pharmacology Product Team Leader                                                                 1991 - 1995

Senior Scientist                                                                                                                                1990 - 1991

·         Pharmacology Product Team Leader, growing molecular pharmacology revenues >15-fold ($1.5 MM - $25 MM/yr)

·         Identified acquisition opportunities for MDS, providing technology due diligence:

o        Acquisition of Skeletech Inc.; ~$10 MM (2005)

o        Acquisition of Signature Biosciences Cellular Dielectric Spectroscopy (CellKeyTM) technology by MDS Sciex, identified, performed technology due diligence, participated in instrument and software design meetings throughout development. ($5MM initial investment 2002)(instrument platform launched 2005)

·         Identified, negotiated, guided collaborations

o        Iconix Pharmaceuticals-MDS PS Chemoinformatics Database Collaboration, responsible for key technology presentation to MDS Executive Management Team, key role in design of pharmacology component - 2002

o        BioSource - MDS PS Strategic Alliance, drafted and negotiated agreement for collaboration on development of new tests and co-marketing - 2005

o        Becton Dickenson (BD)-MDS Pharma Services Biomarker Alliance, identified BD as a potential Alliance partner, initiated discussions between BD and MDS PS.

·         Secured, managed MDS PS major pharmaceutical/biotech company clients (eg. managed  MerckScreen business for MDS PS, >$5MM/yr; advising Merck in initial testing strategies and serving as technical liaison)

·         Lead assay development team, managed molecular pharmacology laboratory (8 staff), (staff developed & validated >300 pharmacology assays)

·         Technical training of sales staff (approx. 3 face-to-face training sessions per year; 8 sales staff)

·         Technical Sales Presentations (Asia, Europe, US; typically approximately 1 - 2 weeks per territory per year; typically 10 client presentations); also provided technical support via teleconference.

·         Technology due diligence for MDS Capital Corp. (continuing role in advising MDS Capital Corp; identified Amnis, Ambit, Aurora BioMed, Signature BioSciences, Speciality Laboratories, Nodality and others)

·         Conceived, Designed & Built key, innovative IT systems & Sales tools including:

o        Fully designed and implemented data delivery system reporting approximately $15 – 20 MM of data per year for 3 years

o        Principal MDS liaison to Arthur Andersen team in development of SMART^TM Data Management System (replaced system I developed)

o        Designed, implemented, maintained MDS Panlabs Client website for 3 years; approximately 3000 html web pages)

o        Designed, implemented, maintained MDS Panlabs Sales Team Website (provided protected access to technical documents, Power Point Presentations and additional supporting information)

o        Initiated, provided initial design, and led team producing MDS PS’ first customer

o        Designed, implemented, maintained integrated sales team quoting and tracking system (system provided complex, fully customized, hyperlinked quotes for customers enabling pricing for routine and customized protocols, 900 assays.  Automated numerous discounting plans and pricing structures; system provided full reporting for Sales Team management)

o        Designed and developed automated sales aids (providing instant access to assay information, translations between different nomenclatures, and providing competitor availability and pricing information)

·         NIH Phase I SBIR Grant:#1 R43 DA 09203-01 (Signal Transduction by Peripheral Cannabinoid Receptors) – wrote pharmacology section of Phase I SBIR grant, performed pharmacology experiments in support of the grant; $50K, 1994

California Biotechnology, Mountain View, CA                                                                     1986 - 1990

(Currently a division of Johnson & Johnson, Inc.)

Senior Scientist                                                                                                                      1988 - 1990

Scientist                                                                                                                                  1986 - 1988

·         Cloned and expressed genes encoding angiogenic growth factors (aFGF, bFGF, VEGF) (note: inhibitors of VEGF are in clinical trials for the treatment of some subtypes of wet AMD)

·         Managed 2 scientists developing cell-based assay methods and performing drug discovery testing

PATENTS

·         Co-Inventor on Submitted International Patent:  Mitchell, R., Mulligan, J., Castillo, G.  2005.  International Application No. PCT/IB2005/000290.  "Fluorescence-Based ADP Detection System"

·         Co-Inventor on US Patent:  Tischer, E.G., J.A. Abraham, J.C. Fiddes, R.L. Mitchell.  1993.  U.S. Patent No. 5,219,739 for "DNA sequences encoding BVEGF120 and HVEGF121 and methods for the production of  bovine and human vascular endothelial cell growth factors, BVEGF120 and HVEGF121". 

·         Co-Inventor on US Patent:  Tischer, E.G., J.A. Abraham, J.C. Fiddes, R.L. Mitchell.  1992.  U.S. Patent No. 5,194,596 for "Production of vascular endothelial cell growth factor".

 EDUCATION

·         NIH Postdoctoral Fellowship, The Salk Institute For Biological Studies, La Jolla, CA 1984 - 1986

·         Ph.D. (Microbiology; virology, molecular biology focus) University of Minnesota, Minneapolis, MN 1984

·         Ph.D. Program (Microbiology; immunology, virology focus) University of Iowa, Iowa City, IA 1976-1978

·         B.A. (honors) (Biology) University of California, Santa Cruz, CA 1976

PROFESSIONAL AFFILIATIONS

·         Chair, MDS PS Scientific Advisory Committee 2004 - 2005, providing scientific guidance for MDS PS strategic growth initiatives

·         Chair, Shoreline Community College Biotechnology Advisory Committee 1997 - 2002

·         Member, Radiotherapeutic Build Team, MDS Nordion, resulting in contracts to label first two Nordion-produced radiotherapeutics, Bexxar^TM and Zevalin^TM

·         Member, Iconix-MDS Collaboration Management Board, providing guidance for DrugMatrixTM, a chemo informatics database used by the pharmaceutical and biotechnology industries

·         Chairman, Panlab's Safety Committee, Vice-Chairman 1993 – 1994

FELLOWSHIPS, AWARDS, DISTINCTIONS

·         Customer Satisfaction Award, MDS Pharma Services                                                                    2002

·         CalBio Professional Recognition Award for Outstanding Achievement                                            1989

·         Bacaner Research Award, Minnesota Medical Foundation, Univ. of Minn.                                        1985

·         NIH Individual Postdoctoral Fellowship Award, The Salk Institute, San Diego                         1984 - 1987

·         USPHS Predoctoral Fellowship, Dept. of Microbiology, Univ. of Minn.                                 1978 - 1982

·         Honors in Biology and College Honors, University of California, Santa Cruz                                    1976

GRANTS

Mitchell, R.L., Lai, Y., Mackie, K.P., and Thomsen, W.J.  Phase I Small Business Innovative Research Grant (NIH) #1 R43 DA 09203-01 Signal Transduction by Peripheral Cannabinoid Receptors, 1994.